Phase Ia/Ib Study of RS-0139 in Patients with a Recurrent, Locally Advanced or Metastatic Solid Tumors

Launched by RS ARASTIRMA EGITIM DANISMANLIK ILAC SANAYI TICARET A.S. · Feb 6, 2020

Keywords

ClinConnect Summary

This clinical trial is testing a new medication called RS-0139 for patients with solid tumors that have come back after treatment or have spread to other parts of the body. The main goal is to find the best dose of this drug, how it behaves in the body, and whether it is safe for patients. The study is divided into two parts and is currently looking for participants aged between 18 and 75 who have not responded to standard treatments or are not suitable for them. To join, patients will need to provide a sample of their tumor tissue and have a life expectancy of at least three months.

If you or a loved one are considering participating, you should be in relatively good health, meaning your organs are functioning well and you have a good performance level (you can carry out daily activities). However, some patients may not be eligible, such as those with certain serious health conditions or those currently involved in other clinical trials. Participants will receive the study drug and will be closely monitored for any side effects. This trial represents a potential new option for patients who have limited treatment choices, and your involvement could help researchers learn more about this new therapy.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients who have consented to participation in the trial.
• • Patients of both sexes aged between 18 and 75 years.
• • Patients with relapsed or refractory solid tumors who have failed available standard therapy or are not candidates for standard therapy.
• • Patients who are willing to provide fresh or archival biopsy material before their participation to identify the integrin expression levels (for Phase Ib only).
• • Patients who completed the previous treatments 21 days before the first dose of the study drug.
• • Patients who have at least three months of life expectancy.
• • Patients with ECOG performance score 0 to 1.
• * Patients with adequate organ function defined as:
• • Hemoglobin ≥10 mg/dl
• • Neutrophil ≥1,500/µL
• • Platelet ≥100,000/µL
• • Creatinine ≤1.5xULN or creatinine clearance ≥60mL/sec/1.73m2
• • Total bilirubin ≤ 1.5xULN
• • AST/ALT ≤2.5xULN; for patients who have confirmed liver metastasis: AST/ALT ≤5xULN.
• • Prothrombin time ≤1.5xULN (in case of no anticoagulant treatment).
• • Normal levels of serum magnesium and potassium concentrations
• Exclusion Criteria:
• • Patients with active and/or uncontrolled central nervous system (CNS) metastasis.
• • Patients who have interstitial lung disease or interstitial pneumonia.
• • Patients who have serious cardiac dysfunction.
• • Patients who have insufficient target organ function.
• • Patients with positive tests for HAV, HBV, HCV or HIV.
• • Patients who experienced grade 3 or higher toxicity related to the previous docetaxel treatment.
• • Female patients who are pregnant or breastfeeding.
• • Male patients with pregnant female partners.
• • Patients enrolled in another clinical trial at the same time or recently completed an investigational drug study and received the last dose of an investigational drug within 30 days or five half-lives (whichever is longer).
• • Patients who have serious medical conditions such as uncontrolled infection or untreated wounds.
• • Patients who have bone marrow transplantation history.
• • Patients who have hypersensitivity to docetaxel, components of RS-0139 and/or other taxanes.
• • Patients taking inhibitors or inducers of CYP3A4, including grapefruit juice and OTC medications such as St. John's Wort.
• • Patients who, in the judgment of the PI, are likely to be non-compliant or unable to cooperate.
• • Patients who cannot be contacted in case of emergency.
• • Patients who are the PI or sub-investigator, research assistant, pharmacist, study coordinator or other staff directly involved in conducting the study.